Kobayashi in $3.2 Billion Buyout Talks After Red-Yeast Scandal

AI Summary

Kobayashi Pharmaceutical Co., involved in a supplement contamination scandal linked to suspected deaths, is reportedly considering a buyout offer exceeding $3.2 billion from private equity investors. This potential deal follows reputational damage to the Japanese health products company.

Kobayashi Pharmaceutical Co., the Japanese health products company that was at the center of a supplement contamination scandal involving suspected deaths, is said to be considering a potential buyout offer of more than ¥500 billion ($3.2 billion) by private equity investors.